Key features and details
- Mouse monoclonal [2642C5a] to Nmnat1/NMNAT
- Suitable for: Dot blot, WB
- Reacts with: Recombinant fragment
- Isotype: IgG1
Product nameAnti-Nmnat1/NMNAT antibody [2642C5a]
See all Nmnat1/NMNAT primary antibodies
DescriptionMouse monoclonal [2642C5a] to Nmnat1/NMNAT
Tested applicationsSuitable for: Dot blot, WBmore details
Species reactivityReacts with: Recombinant fragment
Predicted to work with: Human
This product was previously labelled as Nmnat1
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: PBS, 1% BSA
Concentration information loading...
PurityProtein G purified
Purification notesab84855 was purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum. Filtered through a 0.22 µm membrane.
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab84855 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Dot blot||Use at an assay dependent dilution.|
|WB||Use at an assay dependent dilution. Predicted molecular weight: 32 kDa.|
FunctionCatalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
Tissue specificityWidely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
PathwayCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
Involvement in diseaseLeber congenital amaurosis 9
Sequence similaritiesBelongs to the eukaryotic NMN adenylyltransferase family.
- Information by UniProt
- EC 22.214.171.124 antibody
- LCA9 antibody
- Leber's congenital amaurosis 9 antibody
Anti-Nmnat1/NMNAT antibody [2642C5a] (ab84855) + Immunogen (Recombinant Human Nmnat1/NMNAT fragment)
Predicted band size: 32 kDa
Observed band size: 35 kDa why is the actual band size different from the predicted?
ab84855 has not yet been referenced specifically in any publications.